{'fraction_non_alphanumeric': 0.02891566265060241, 'fraction_numerical': 0.004819277108433735, 'mean_word_length': 5.9222222222222225, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A double–blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a noradrenaline uptake inhibitor, in endogenous depression

A comparative evaluation of zimelidine, a potent and selective serotonin (5‐HT) uptake inhibitor, and desipramine, a potent nor‐adrenaline (NA) uptake inhibitor, was carried out in a 4‐week randomized, double‐blind study in 65 hospitalized patients with endogenous depression. For evaluation of the clinical effect, Hamilton Rating Scale for depression (HRS) and a 14‐item scale chosen from the Comprehensive Psychopathological Rating Scale (CPRS) were used. The concentration of drug in plasma was determined on the same days as the clinical ratings. There was no significant difference in the overall therapeutic effect between the two drugs. However, zimelidine had significantly better effect on anxiety. Although both agents were well tolerated, the zimelidine‐treated patients reported significantly less severe anticholinergic side effects. Body weight did not change significantly in either treatment group. In the total material there were no significant correlations between plasma concentrations of zimelidine, norzimelidine and desipramine and the amelioration score of either HRS and CPRS.